Status:
COMPLETED
Magnesium Treatment in Hypoparathyroidism
Lead Sponsor:
University of Tartu
Conditions:
Hypoparathyroidism
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Cal...
Eligibility Criteria
Inclusion
- primary or secondary hypoparathyroidism
- treatment with calcium plus vitamin D analogue
- ionized calcium 1,0-1,29 mmol/L
- magnesium level 0,7-1,05 mmol/L
- TSH 0.1- 10 imU/L
Exclusion
- any other disease known to influence plasma Ca level
- pregnancy
- creatinine \> 150 microM/L
- patient has used supplementary magnesium within 2 previous months
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00824226
Start Date
January 1 2009
End Date
August 1 2011
Last Update
August 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tartu University Hospital
Tartu, Estonia, 50406